Next 10 |
Global Blood Therapeutics (NASDAQ:GBT) may be a potential acquisition candidate in the biotech space following Pfizer (PFE)'s deal to acquire Biohaven Pharmaceutical for about $11.6 billion, according to a Wedbush analyst. "In light of Pfizer’s $12 billion acquisition of Biohaven Pharm...
New real-world evidence data on Oxbryta ® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASD...
After market hours on Wednesday, Global Blood Therapeutics (NASDAQ: GBT) released a first-quarter earnings report that investors didn't digest well. As a result, the following day, the stock fell by 8% -- a steep rate, even on a very bearish day when the S&P 500 index declin...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...
Global Blood Therapeutics, Inc. (GBT) Q1 2022 Earnings Conference Call May 04, 2022 4:30 PM ET Company Participants Steven Immergut – Senior Vice Preside, Head-Corporate Communications and Investor Relations Ted Love – President and Chief Executive Officer Jeff Farrow – C...
Global Blood Therapeutics press release (NASDAQ:GBT): Q1 GAAP EPS of -$1.26 beats by $0.06. Revenue of $55.16M (+41.3% Y/Y) misses by $0.97M. For further details see: Global Blood Therapeutics GAAP EPS of -$1.26 beats by $0.06, revenue of $55.16M misses by $0.97M
Achieved Oxbryta ® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 y...
Global Blood Therapeutics (NASDAQ:GBT) is scheduled to announce Q1 earnings results on Wednesday, May 4th, after market close. The consensus EPS Estimate is -$1.36 and the consensus Revenue Estimate is $56.13M (+43.8% Y/Y). Over the last 1 year, GBT has beaten EPS estimates 25% of the time an...
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient communities starting with sickle cell disease (SCD), today released its inaugural environm...
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a con...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
New real-world evidence data on Oxbryta ® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASD...
After market hours on Wednesday, Global Blood Therapeutics (NASDAQ: GBT) released a first-quarter earnings report that investors didn't digest well. As a result, the following day, the stock fell by 8% -- a steep rate, even on a very bearish day when the S&P 500 index declin...
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...